SCHEMBL7671600

SCHEMBL7671600

Cc1ccccc1C(=O)Nc1ccc(S(=O)(=O)NCC(=O)OC(C)(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
HTT P42858 1/20 0.51
HSD17B10 Q99714 1/20 0.51
KDM4E B2RXH2 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
HPGD P15428 1/20 0.49
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
FFAR1 O14842 1/20 0.47
GPR27 Q9NS67 2/20 0.47
AVPR2 P30518 1/20 0.47
LMNA P02545 2/20 0.46
THRB P10828 1/20 0.45
TYK2 P29597 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7665180 0.88 KDM4E (0.56) HTTHSD17B10KDM4ESMN1; SMN2NPC1
SCHEMBL7670478 0.88 TP53 (0.56) ALDH1A1HSD17B10SMN1; SMN2GAAKMT2A
SCHEMBL7669835 0.87 RXFP1 (0.61) ALDH1A1HSD17B10SMN1; SMN2NPC1RAB9A
SCHEMBL7669734 0.86 MEN1 (0.52) ALDH1A1HTTHSD17B10KDM4ENPC1
SCHEMBL7669548 0.85 ALDH1A1 (0.64) ALDH1A1HTTHSD17B10SMN1; SMN2RAB9A
SCHEMBL7582747 0.85 LMNA (0.65) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL7663119 0.83 FFAR1 (0.60) ALDH1A1HTTHSD17B10KDM4ESMN1; SMN2
SCHEMBL7663740 0.83 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL7675460 0.83 SGMS2 (0.58) ALDH1A1HSD17B10MEN1GAAKMT2A
SCHEMBL7669640 0.82 GHSR (0.53) ALDH1A1HTTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed